What the Study Actually Measured

The design matters here. The trial randomized approximately 180 adults with obesity, defined as a body mass index of 30 or above, to weekly subcutaneous VK2735 or placebo for 21 weeks. After Week 21, participants moved onto maintenance regimens of monthly, every other week, or continued weekly injections, or placebo, for a further 12 weeks. Total duration was 33 weeks.

Viking states plainly that the objectives were to evaluate safety, tolerability and pharmacokinetics, and that change in body weight was an exploratory endpoint. That is an important distinction. These are encouraging numbers from a study that was not powered to prove efficacy, and the release never labels the trial a Phase 2 or Phase 3. Readers should treat the weight figures as directional rather than registrational.

The Induction Phase Set a High Bar

Across the weekly dosing cohorts, weight loss at Week 21 ranged from roughly 16% to 19%, against approximately 0% for placebo, with statistical significance at p<0.0001 against both baseline and placebo. Broken out by dose, mean reductions were 16.3% at 15 mg, 17.8% at 17.5 mg, 18.7% at 20 mg and 17.1% at 22.5 mg.

Responder rates tell the same story from another angle. In the combined treatment groups, 98% of participants lost at least 5% of body weight, 90% lost at least 10%, 65% lost at least 15% and 32% lost at least 20%. The corresponding placebo figures were 13%, 0%, 0% and 0%.

One caveat belongs beside those percentages. The cohorts were not evenly sized. The 17.5 mg group carried 118 participants, while the 15 mg, 20 mg and 22.5 mg groups held 14, 15 and 14 respectively, against 15 on placebo. The headline dose is well populated; the dose-response curve around it rests on small numbers.

The Maintenance Result Is the Actual News

Participants who moved to every other week dosing retained up to 97% of the weight loss achieved during induction, with individual cohorts at 83%, 90% and 97%. Those who moved to monthly dosing retained up to 90%, with cohorts landing between 82% and 90%. Placebo patients retained 61%. Both comparisons cleared significance against placebo at p<0.0001.

Meanwhile, the cohort that simply stayed on 17.5 mg weekly reached 21.7% weight loss from baseline at Week 33, against a 0.3% gain for placebo, which is where the 22% placebo-adjusted headline comes from. Viking notes that weight loss in this group was progressive through 33 weeks with no plateau observed. The word to watch throughout is “up to,” since 97% and 90% describe the best performing cohort in each arm rather than an average across all of them.

Tolerability Held Up When Dosing Thinned Out

During the 12-week maintenance window, rates of gastrointestinal adverse events including vomiting, nausea, diarrhea and constipation were not meaningfully different from placebo. During the 21-week induction phase, one subject, or 1%, discontinued because of an adverse event. Adverse events were most commonly gastrointestinal and characterized as mild. Notably, the study used an accelerated two-week titration schedule, and GI event rates still came in similar to the prior Phase 2 study, which titrated over three weeks.

Chief Executive Officer Brian Lian said the results “continue to demonstrate the significance of VK2735's unique and differentiated half-life and PK profile, which appear to enable an effective new approach to achieving and maintaining the weight loss goals of patients living with obesity.” Louis Aronne, MD, FACP, former president of The Obesity Society, added that the findings “provide a basis for improved dosing flexibility for both clinicians and their patients.” Viking plans to explore oral maintenance regimens in a second part of the study, and VK2735 is already in Phase 3, where VANQUISH 1 is enrolling an estimated 4,500 participants with primary completion targeted for July 2027.

The Competitive Backdrop Has Shifted Fast

Context explains why maintenance now matters more than peak efficacy. Two oral incretins reached the market inside the past year. The FDA approved Eli Lilly's orforglipron, branded Foundayo, on April 1, 2026, with Lilly reporting an average 12.4% reduction at the highest dose at Week 72 among patients who stayed on treatment. Novo Nordisk's oral semaglutide 25 mg, the Wegovy pill, was approved on December 22, 2025, with mean weight loss of 16.6% in the OASIS 4 trial. Against a field where efficacy is increasingly commoditized, adherence and dosing convenience become the differentiators, and the FDA's January 2025 draft guidance sets the efficacy bar at a 5% placebo-adjusted difference, a threshold every serious candidate now clears comfortably.

The Spending Behind It

Viking reported cash, cash equivalents and short-term investments of $502 million at June 30, 2026, down from $706 million at the end of 2025. Research and development expense reached $115.8 million for the quarter against $60.2 million a year earlier, and the net loss widened to $128.0 million, or $1.10 per share, from $65.6 million, or $0.58. The company has no product revenue. Its pipeline also carries an oral VK2735 formulation, the amylin agonist VK3019, and thyroid receptor beta programs VK2809 and VK0214. Running two Phase 3 obesity trials is expensive, and the pace of cash consumption is the number to track alongside the clinical data.

Strategic Investment Summary

• Maintenance Data Reported: Viking Therapeutics (NASDAQ: VKTX) released topline results from the VK2735-102 maintenance study on September 22, 2026, in approximately 180 adults with obesity.
• Dosing Can Be Reduced: Patients moving to every other week dosing retained up to 97% of induction weight loss and those moving to monthly dosing retained up to 90%, against 61% for placebo.
• Continued Weekly Dosing: The cohort remaining on 17.5 mg weekly reached 21.7% weight loss from baseline at Week 33 against a 0.3% placebo gain, with no plateau observed.
• Exploratory, Not Registrational: The study's stated objectives were safety, tolerability and pharmacokinetics, with weight change assessed as an exploratory endpoint, and the release assigns the trial no phase designation.
• Tolerability in Maintenance: Gastrointestinal adverse event rates during the 12-week maintenance window were not meaningfully different from placebo, and one subject, or 1%, discontinued for an adverse event during induction.
• Balance Sheet: Cash and short-term investments stood at $502 million at June 30, 2026, down from $706 million at year end, with quarterly research and development spending of $115.8 million and a net loss of $128.0 million.

Find out more about the latest corporate developments and financial reports at the Viking Therapeutics investor relations site.

The post Viking Therapeutics Holds 90% of Weight Loss on Monthly Dosing, Answering the Question the Obesity Market Keeps Asking appeared first on PRISM MarketView.

COMTEX_493091174/2927/2026-09-22T11:00:49